Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says

MT Newswires Live09-26 01:33

Xencor's (XNCR) upcoming dose-expansion data readout for XmAb819 to treat clear cell renal cell carcinoma has potential for improved response rates and more mature durability results, Wedbush Securities said in a Friday research report.

XmAb819 has been evaluated in a more pretreated population, and meaningful activity in this setting could establish differentiation in efficacy and drive upside, according to the note.

If the expansion cohort maintains the 25% overall response rate and 70% disease control rate already observed in dose-escalation, while dose-escalation cohorts show progression-free survival in line with or modestly above the established 6- to 7-month range, the drug remains on track for its registrational path, supporting continued appreciation of the stock, analysts wrote.

Wedbush reiterated its outperform rating and a $30 price target on the stock.

Price: 23.72, Change: -0.16, Percent Change: -0.69

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2670042966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-26 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670042966","market":"sg","top_or_hot":-1,"title":"Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Xencor's (XNCR) upcoming dose-expansion data readout for XmAb819 to treat clear cell renal cell carcinoma has potential for improved response rates and more mature durability results, Wedbush Securities said in a Friday research report.</p><p>XmAb819 has been evaluated in a more pretreated population, and meaningful activity in this setting could establish differentiation in efficacy and drive upside, according to the note.</p><p>If the expansion cohort maintains the 25% overall response rate and 70% disease control rate already observed in dose-escalation, while dose-escalation cohorts show progression-free survival in line with or modestly above the established 6- to 7-month range, the drug remains on track for its registrational path, supporting continued appreciation of the stock, analysts wrote.</p><p>Wedbush reiterated its outperform rating and a $30 price target on the stock.</p><p>Price: 23.72, Change: -0.16, Percent Change: -0.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXencor's XmAb819 Data Could Support Registrational Path, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-26 01:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Xencor's (XNCR) upcoming dose-expansion data readout for XmAb819 to treat clear cell renal cell carcinoma has potential for improved response rates and more mature durability results, Wedbush Securities said in a Friday research report.</p><p>XmAb819 has been evaluated in a more pretreated population, and meaningful activity in this setting could establish differentiation in efficacy and drive upside, according to the note.</p><p>If the expansion cohort maintains the 25% overall response rate and 70% disease control rate already observed in dose-escalation, while dose-escalation cohorts show progression-free survival in line with or modestly above the established 6- to 7-month range, the drug remains on track for its registrational path, supporting continued appreciation of the stock, analysts wrote.</p><p>Wedbush reiterated its outperform rating and a $30 price target on the stock.</p><p>Price: 23.72, Change: -0.16, Percent Change: -0.69</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XNCR","symbol_name":"Xencor Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2670042966","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670042966","pubTimestamp":1790357624,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Xencor's  upcoming dose-expansion data readout for XmAb819 to treat clear cell renal cell carcinoma has potential for improved response rates and more mature durability results, Wedbush Securities said in a Friday research report.XmAb819 has been evaluated in a more pretreated population, and meaningful activity in this setting could establish differentiation in efficacy and drive upside, according to the note.If the expansion cohort maintains the 25% overall response rate and 70% disease control rate already observed in dose-escalation, while dose-escalation cohorts show progression-free survival in line with or modestly above the established 6- to 7-month range, the drug remains on track for its registrational path, supporting continued appreciation of the stock, analysts wrote.Wedbush reiterated its outperform rating and a $30 price target on the stock.Price: 23.72, Change: -0.16, Percent Change: -0.69","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XNCR":"Xencor Inc","BK4139":"生物科技"},"translate_title":"Wedbush 表示，Xencor 的 XmAb819 数据可以支持注册路径","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XNCR":1.5},"content_text":"Xencor's (XNCR) upcoming dose-expansion data readout for XmAb819 to treat clear cell renal cell carcinoma has potential for improved response rates and more mature durability results, Wedbush Securities said in a Friday research report.XmAb819 has been evaluated in a more pretreated population, and meaningful activity in this setting could establish differentiation in efficacy and drive upside, according to the note.If the expansion cohort maintains the 25% overall response rate and 70% disease control rate already observed in dose-escalation, while dose-escalation cohorts show progression-free survival in line with or modestly above the established 6- to 7-month range, the drug remains on track for its registrational path, supporting continued appreciation of the stock, analysts wrote.Wedbush reiterated its outperform rating and a $30 price target on the stock.Price: 23.72, Change: -0.16, Percent Change: -0.69","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670042966","isCrawlerRequest":true}